These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1139 related items for PubMed ID: 15199494

  • 1. Venous and arterial thrombosis during oral contraceptive use: risks and risk factors.
    Tanis BC, Rosendaal FR.
    Semin Vasc Med; 2003 Feb; 3(1):69-84. PubMed ID: 15199494
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular risk of oral contraceptives. Low, and mainly in women at risk.
    Prescrire Int; 1998 Aug; 7(36):118-24. PubMed ID: 10342951
    [Abstract] [Full Text] [Related]

  • 3. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users.
    Cole JA, Norman H, Doherty M, Walker AM.
    Obstet Gynecol; 2007 Feb; 109(2 Pt 1):339-46. PubMed ID: 17267834
    [Abstract] [Full Text] [Related]

  • 4. [Vascular disease and hormonal treatment--epidemiology].
    Vessey MP.
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):121-6. PubMed ID: 12280197
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Oral contraceptives, hormone replacement therapy and thrombosis.
    Rosendaal FR, Helmerhorst FM, Vandenbroucke JP.
    Thromb Haemost; 2001 Jul; 86(1):112-23. PubMed ID: 11486996
    [Abstract] [Full Text] [Related]

  • 9. Oral contraceptives and the risk of myocardial infarction.
    Tanis BC, van den Bosch MA, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A, van der Graaf Y, Rosendaal FR.
    N Engl J Med; 2001 Dec 20; 345(25):1787-93. PubMed ID: 11752354
    [Abstract] [Full Text] [Related]

  • 10. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
    Kemmeren JM, Algra A, Meijers JC, Bouma BN, Grobbee DE.
    Thromb Haemost; 2002 Feb 20; 87(2):199-205. PubMed ID: 11859850
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens.
    van Vliet HA, Frolich M, Christella M, Thomassen LG, Doggen CJ, Rosendaal FR, Rosing J, Helmerhorst FM.
    Hum Reprod; 2005 Feb 20; 20(2):563-8. PubMed ID: 15539435
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Significance of hereditary thrombophilia for risk of thrombosis with oral contraceptives].
    Bauersachs R, Lindhoff-Last E, Ehrly AM, Kuhl H.
    Zentralbl Gynakol; 1996 Feb 20; 118(5):262-70. PubMed ID: 8701622
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.